ChartRow logo
Data provided bySource: Twelve Data
ASND
$271.19-0.20%
as of close, Nov 17, 2026
☾ AH $271.19 -0.20%
Share this page

ASND financial statements

The full income statement, balance sheet, and cash-flow statement for Ascendis Pharma A/S Ordinary Share (ASND), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +152.6%10Y CAGR +56.9%
$814.9M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Gross profit

5Y CAGR +145.5%5Y CAGR +145.5%
$707.5M FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y n/m5Y n/m
— FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Net income

5Y n/m10Y n/m
−$258M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

10Y n/m
−$4.25 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating cash flow

5Y n/m10Y n/m
$61M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Capital expenditure

5Y CAGR −3.3%5Y CAGR −3.3%
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y n/m5Y n/m
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Shares (diluted)

10Y +155.0%
60.6M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Every ASND chart on Trends →

Shares outstanding (point-in-time)

2017-12 33.6M2018-12 42.1M2019-12 48.0M2020-12 53.8M2021-12 56.9M2022-12 57.2M2023-12 57.7M2024-12 60.7M2025-12 62.0M+84.3% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue815M+107.2%393M+36.4%288M+435.8%53.8M+485.2%9.20M+16.0%
707M+104.8%345M+43.7%240M+485.4%41.1M+716.0%5.03M-36.5%
Cost of revenue107M+124.3%47.9M-0.3%48.0M+276.0%12.8M+206.4%4.17M
Research & development344M+3.5%332M-25.7%447M+12.0%399M+14.1%350M+17.6%
Operating income———-591M-10.6%-534M-41.8%
Interest expense234M+116.2%108M+127.1%47.7M-10.3%53.1M+1048.2%4.63M-95.0%
Pre-tax income-241M+40.4%-404M+21.3%-513M+15.6%-608M-33.9%-454M+5.0%
Income tax17.4M+232.3%5.24M-33.7%7.90M+39.6%5.66M+1403.2%-434K-73.8%
-258M+36.9%-409M+21.4%-521M+15.1%-614M-35.2%-454M+5.0%
Net income to common-258M+36.9%-409M+21.4%-521M+15.1%-614M-35.2%-454M+5.0%
-$4.25+39.8%-$7.06+23.6%-$9.25+15.5%-$10.94-32.2%-$8.28
EPS (basic)-$4.25+39.8%-$7.06+23.6%-$9.25+15.5%-$10.94-32.2%-$8.28
Weighted-avg shares (basic)60.6M+4.7%57.9M+2.9%56.3M+0.4%56.1M+2.4%54.8M+8.2%
Weighted-avg shares (diluted)60.6M+4.7%57.9M+2.9%56.3M+0.4%56.1M+2.4%54.8M
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.30B+18.2%1.10B+42.1%776M-21.5%988M+8.3%913M+0.3%
Cash & equivalents724M+24.5%582M+34.3%433M-9.0%476M-5.8%505M-29.7%
Inventory355M+15.4%307M+33.2%231M+65.0%140M+63.7%85.4M
1.53B+24.9%1.23B+34.5%911M-21.8%1.17B-5.1%1.23B+2.0%
Property, plant & equipment172M+67.8%103M-16.0%122M-11.6%138M-3.2%143M+7.4%
Total non-current assets228M+84.6%123M-9.1%136M-23.8%178M-43.7%316M+7.2%
1.26B+33.2%944M+16.1%813M+343.7%183M+61.2%114M+75.0%
Short-term & current debt806M+27.4%633M+5006.3%12.4M-54.4%27.2M+243.4%7.92M
1.72B+29.0%1.34B+24.6%1.07B+21.3%884M+287.9%228M+31.4%
Long-term debt453M+19.4%379M+54.1%246M-52.4%517M+365.8%111M
-191M-74.2%-110M+31.7%-161M-157.1%282M-71.8%1.00B-3.0%
Total equity incl. non-controlling-191M-74.2%-110M+31.7%-161M-157.1%282M-71.8%1.00B-3.0%
Common shares issued62.0M+2.1%60.7M+5.2%57.7M+1.0%57.2M+0.4%56.9M+5.9%
Shares outstanding (cover)62.0M+2.1%60.7M+5.2%57.7M+1.0%57.2M+0.4%56.9M+5.9%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Cash from operations61.0M+118.4%-331M+34.5%-505M+3.1%-521M-5.6%-494M-59.6%
Capital expenditure——2.64M-82.7%15.2M-45.6%28.0M+23.8%
Free cash flow——-508M+5.3%-537M-2.8%-522M-57.1%
Acquisitions0.000.000.00—0.00
Long-term debt issued0.00-100.0%145M-1.5%147M-72.2%529M0.00
Long-term debt repaid24.8M+102.1%12.3M+8.9%11.3M+68.8%6.69M0.00
Common stock issued0.00-100.0%335M0.000.00-100.0%435M-34.3%
Common stock repurchased19.7M0.00-100.0%115M+2.8%112M+336.8%25.6M
Dividends paid0.000.000.000.000.00
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap13.2B+58.2%8.36B+16.1%7.20B+3.5%6.95B-9.2%7.66B-14.6%
P/S16.2×-23.6%21.2×-84.1%133.7×-82.3%755.9×-9.2%832.7×-26.4%
P/B——25.5×+267.6%6.9×-9.2%7.7×-11.9%
Source filing20-F20-F20-F20-F20-F

About this data

Source: ASND’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ASND filings on SEC EDGAR → Not investment advice.